Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Jun;19(6):1078–1081. doi: 10.1128/aac.19.6.1078

Segregation of 5-Fluorocytosine-Resistant Variants by Candida albicans

William L Whelan 1, Everett S Beneke 2, Alvin L Rogers 2, David R Soll 1
PMCID: PMC181613  PMID: 7023383

Abstract

Spontaneous production of 5-fluorocytosine-resistant variants by three Candida albicans isolates is due to segregation from a preexisting heterozygous state.

Full text

PDF
1078

Images in this article

1079Image
on p.1079
1079Image
on p.1079

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auger P., Dumas C., Joly J. A study of 666 strains of Candida albicans: correlation between serotype and susceptibility to 5-fluorocytosine. J Infect Dis. 1979 May;139(5):590–594. doi: 10.1093/infdis/139.5.590. [DOI] [PubMed] [Google Scholar]
  2. Bennett J. E. Chemotherapy of systemic mycoses (first of two parts). N Engl J Med. 1974 Jan 3;290(1):30–32. doi: 10.1056/NEJM197401032900107. [DOI] [PubMed] [Google Scholar]
  3. Bennett J. E. Chemotherapy of systemic mycoses (second of two parts). N Engl J Med. 1974 Feb 7;290(6):320–323. doi: 10.1056/NEJM197402072900607. [DOI] [PubMed] [Google Scholar]
  4. Diasio R. B., Bennett J. E., Myers C. E. Mode of action of 5-fluorocytosine. Biochem Pharmacol. 1978 Mar 1;27(5):703–707. doi: 10.1016/0006-2952(78)90507-5. [DOI] [PubMed] [Google Scholar]
  5. Grenson M. The utilization of exogenous pyrimidines and the recycling of uridine-5'-phosphate derivatives in Saccharomyces cerevisiae, as studied by means of mutants affected in pyrimidine uptake and metabolism. Eur J Biochem. 1969 Dec;11(2):249–260. doi: 10.1111/j.1432-1033.1969.tb00767.x. [DOI] [PubMed] [Google Scholar]
  6. Hoeprich P. D. Chemotherapy of systemic fungal diseases. Annu Rev Pharmacol Toxicol. 1978;18:205–231. doi: 10.1146/annurev.pa.18.040178.001225. [DOI] [PubMed] [Google Scholar]
  7. Holt R. J. Clinical problems with 5-fluorocytosine. Mykosen. 1978 Nov;21(11):363–369. doi: 10.1111/j.1439-0507.1978.tb01598.x. [DOI] [PubMed] [Google Scholar]
  8. Jund R., Lacroute F. Genetic and physiological aspects of resistance to 5-fluoropyrimidines in Saccharomyces cerevisiae. J Bacteriol. 1970 Jun;102(3):607–615. doi: 10.1128/jb.102.3.607-615.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Olaiya A. F., Sogin S. J. Ploidy determination of Canadida albicans. J Bacteriol. 1979 Dec;140(3):1043–1049. doi: 10.1128/jb.140.3.1043-1049.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Polak A. 5-Fluorocytosine--current status with special references to mode of action and drug resistance. Contrib Microbiol Immunol. 1977;4:158–167. [PubMed] [Google Scholar]
  11. Polak A., Wain W. H. The influence of 5-fluorocytosine on nucleic acid synthesis in Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus. Chemotherapy. 1977;23(4):243–259. doi: 10.1159/000221992. [DOI] [PubMed] [Google Scholar]
  12. Schönebeck J., Anséhn S. 5-Fluorocytosine resistance in candida spp. and Torulopsis glabrata. Sabouraudia. 1973 Mar;11(1):10–20. doi: 10.1080/00362177385190041. [DOI] [PubMed] [Google Scholar]
  13. Whelan W. L., Magee P. T. Natural heterozygosity in Candida albicans. J Bacteriol. 1981 Feb;145(2):896–903. doi: 10.1128/jb.145.2.896-903.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Whelan W. L., Partridge R. M., Magee P. T. Heterozygosity and segregation in Candida albicans. Mol Gen Genet. 1980;180(1):107–113. doi: 10.1007/BF00267358. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES